Adam Brufsky, MD, PhD, University of Pittsburgh, Pittsburgh, PA, discusses identifying drivers of first-line hormone receptor-positive, HER2-negetive (HR+/HER2-) metastatic breast cancer treatment choices. The analysis of real-world data regarding the treatment of HR+/HER2 metastatic breast cancer in the first-line has revealed that despite demonstrated clinical benefits of first line (1L) cyclin-dependent kinases 4/6 inhibitors (CDK4/6i) and their preferred status in the NCCN guidelines, many patients still receive chemotherapy or endocrine monotherapy. An online survey was distributed to oncologists in the US, including questions surrounding where they were trained, the sources of their information, and the characteristics of their patients to describe self-reported clinical and non-clinical factors considered by US oncologists in selection of 1L treatment for HR+/HER2- metastatic breast cancer. Anticipated treatment efficacy and safety/tolerability were ranked as the most important factor considered by oncologists when selecting 1L treatments. Additionally, CDK4/6i prescribing was most strongly correlated with patient Medicare eligibility. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
